Comparative Pharmacology
Head-to-head clinical analysis: CINOXACIN versus GATIFLOXACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CINOXACIN versus GATIFLOXACIN.
CINOXACIN vs GATIFLOXACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II), blocking DNA replication and transcription.
Gatifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination.
1 g orally twice daily for 7-14 days.
400 mg orally or intravenously once daily
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours in healthy adults. Prolonged in renal impairment (up to 20-30 hours in anuria).
Terminal elimination half-life 7-14 hours (mean ~10 hours in healthy adults); prolonged in renal impairment (up to 40 hours with CrCl <30 mL/min)
Clinical Note
moderateCinoxacin + Digoxin
"Cinoxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGatifloxacin + Digoxin
"Gatifloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCinoxacin + Digitoxin
"Cinoxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGatifloxacin + Digitoxin
"Gatifloxacin may decrease the cardiotoxic activities of Digitoxin."
Primarily renal excretion as unchanged drug (approximately 60-70%) and as glucuronide conjugates (approximately 20-30%). Biliary/fecal excretion accounts for less than 5%.
Primarily renal excretion (70-87% unchanged in urine) via glomerular filtration and tubular secretion; ~10% biliary/fecal
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic